Emerging drugs for the treatment of atopic dermatitis: a focus on phase 2 and phase 3 trials

Introduction Atopic dermatitis (AD) is an inflammatory skin condition that affects millions of pediatric and adult patients with well-studied impact on morbidity and quality of life. Management occurs in a stepwise fashion beginning with preventative measures before immunomodulators are introduced. However, challenges remain in treatment of moderate to severe atopic dermatitis that is refractory to first and second-line treatments and there are only few topical anti-inflammatory options, especially for pediatric patients.